$1.29
0.021.57%
Pre-Market: Jul 12, 6:59 PM EDT
15 minutes delayed
RenovoRx
RNXTNASDAQ
Latest news for RenovoRx (NASDAQ:RNXT) Stock
RenovoRx Stock (NASDAQ: RNXT)
Categories: All
Monday, July 08, 2024
Wednesday, June 26, 2024
Monday, June 17, 2024
Friday, June 14, 2024
Wednesday, June 12, 2024
Thursday, May 30, 2024
Tuesday, May 21, 2024
Thursday, April 18, 2024
Monday, April 08, 2024
Friday, February 02, 2024
Wednesday, January 31, 2024
Wednesday, January 10, 2024
Tuesday, January 02, 2024
Monday, January 01, 2024
Friday, December 29, 2023
Thursday, December 28, 2023
Thursday, December 21, 2023
Tuesday, December 19, 2023
Friday, December 15, 2023
Thursday, December 14, 2023
Wednesday, December 13, 2023
Wednesday, November 15, 2023
Tuesday, November 14, 2023
Friday, August 18, 2023
Thursday, August 17, 2023
Monday, August 07, 2023
Thursday, July 20, 2023
Thursday, June 29, 2023
- Why RenovoRx Stock Is Moving Today
- Microcap Biotech Stock RenovoRx is Shooting Higher Today: Here's Why
- Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Market-Moving News for June 29th
- RenovoRx shares are trading higher after the ...
- RenovoRx Announces Interim Phase III Data Dem...
Thursday, June 01, 2023
Thursday, May 25, 2023
Monday, May 15, 2023
Monday, April 03, 2023
Thursday, March 30, 2023
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- RenovoRx shares are trading lower after the c...
- RenovoRx Shares Resume Trade Following Circui...
- RenovoRx, Inc. Announces $5M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules With A Certain Institutional Investor For The Purchase And Sale Of 1,557,632 Shares Of Common Stock At A Price Of $3.21/Share; Shares Halted On Circuit Breaker
- US Stocks Open Higher; Dow Jumps 150 Points
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- RenovoRx Announces New Data From Phase III Clinical Trial Interim Analysis: 60% Survival Benefit And Fewer Side Effects Than Systemic Chemotherapy